Nintedanib - A Comprehensive Review

Overview

Nintedanib is a drug used to treat idiopathic pulmonary fibrosis (IPF), a progressive and frequently deadly lung illness characterized by lung tissue scarring. Nintedanib was approved by the Food and Drug Administration (FDA) on October 15th, 2014.

Indications:

Indications for Nintedanib include:

• Idiopathic Pulmonary Fibrosis (IPF): A chronic lung illness characterized by lung scarring produced by an unknown source.

• Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD): Also known as scleroderma-associated ILD, this is a potentially deadly lung scarring condition.

• Chronic Fibrosing Interstitial Lung Disorders (ILD): A category of continuing illnesses characterized by increasing lung scarring.

Contraindications:

Contraindications of Nintedanib include:

• Hepatic Impairment: The safety and effectiveness of Nintedanib in patients with Child-Pugh B and C hepatic impairment have not been studied. It is not suggested that Nintedanib be used to treat individuals with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.

• Pregnancy and Breastfeeding: Nintedanib is not suggested for usage during pregnancy or breastfeeding since it may damage the fetus. It is also not advised to use during nursing.

• Bleeding Disorders: Nintedanib has been linked to an increase in the risk of bleeding. Patients having a history of bleeding problems or who are taking blood thinners should use Nintedanib with care and under the supervision of a doctor.

• Gastrointestinal Perforation: Nintedanib has been linked to a higher risk of gastrointestinal perforation. In individuals with a history of this problem, it should be taken with care.

• Hypersensitivity: Nintedanib is contraindicated in individuals who have a history of hypersensitivity to the medicine or any of its components.

Dosage Forms and Available Strengths

Nintedanib capsules are available in two strengths:

• 100 milligrams (mg): This dose is appropriate for people with mild hepatic impairment.

• 150 milligrams: Most patients are prescribed 150 mg twice a day, typically 12 hours apart.

To avoid potential gastrointestinal adverse effects, the capsules should be consumed whole with liquids and taken with meals.

Warnings and Precautions

Warnings and precautions of Nintedanib include:

• Gastrointestinal Effects: Nintedanib can induce stomach or bowel issues, including nausea, vomiting, diarrhea, and abdominal discomfort. These consequences can be severe in some circumstances. If these symptoms persist or worsen, patients should see their doctor.

• Risk of Bleeding: Nintedanib may increase the risk of bleeding. If patients have unusual bleeding, bruises, or wounds that do not heal, they should seek medical assistance.

• Cardiovascular Events: With Nintedanib, there is an increased risk of heart attack or stroke. If a patient has chest pain or discomfort, dizziness, headache, or other signs of a cardiovascular event, they should call their doctor.

• Gastrointestinal Perforation: Nintedanib has the potential to create a rip (perforation) in the stomach or intestines. If patients feel significant stomach discomfort that does not go away or see blood in their stool, they should seek emergency medical assistance.

• Hepatic Impairment: Nintedanib has been linked to liver issues. Therefore, patients should be closely watched for symptoms of liver injury, such as jaundice, dark urine, or prolonged nausea and vomiting.

• Other Precautions: Nintedanib has been linked to proteinuria, weight loss, and respiratory issues. Before beginning Nintedanib medication, patients should discuss their medical history and any current problems with their healthcare practitioner.

For Patients

What Is Idiopathic Pulmonary Fibrosis?

Idiopathic pulmonary fibrosis (IPF) is a dangerous and progressive lung condition that causes scarring of the lung tissue, making breathing more difficult. It is the most prevalent kind of pulmonary fibrosis and typically affects adults aged 70 to 75, with people under 50 being uncommon.

What Is the Clinical Condition That Requires Prescription of Nintedanib?

The clinical conditions for which Nintedanib is recommended include:

• Idiopathic pulmonary fibrosis (IPF).

• Chronic fibrosing interstitial lung diseases are a set of lung illnesses marked by progressive scarring of lung tissue, resulting in difficulty breathing and a loss in lung function.).

• Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a kind of interstitial lung disease that affects people who have systemic sclerosis (SSc), a rare autoimmune connective tissue disease that causes immunological dysregulation and progressive fibrosis.

How Effective Is Nintedanib?

Nintedanib has been found to delay the deterioration in lung function and lower the likelihood of acute exacerbations in people with idiopathic pulmonary fibrosis (IPF). Clinical studies have shown that it is effective in controlling this progressive and frequently deadly lung illness.

The effectiveness of Nintedanib in IPF includes:

• Slowing Disease Progression: Research has shown that Nintedanib can dramatically delay the reduction in forced vital capacity (FVC), a marker of lung function, in people with IPF. The medicine slows the advancement of lung fibrosis (pulmonary fibrosis is a dangerous lung condition that causes the lung tissue to thicken and scar, making it difficult for the lungs to function correctly), potentially postponing the worsening of respiratory symptoms.

• Reducing Acute Exacerbations: Nintedanib has also been linked to a lower incidence of acute exacerbations in IPF patients. Acute exacerbations can cause a rapid and severe worsening of respiratory symptoms and are frequently linked with a poor prognosis.

• Improving Quality of Life: Slowing disease progression and lowering the risk of exacerbation can help people with IPF have a better quality of life. Nintedanib may assist patients in retaining a greater level of daily functioning and exercise by controlling symptoms and preserving lung function.

How Is Nintedanib Administered?

• Nintedanib is normally taken orally with meals twice daily, about 12 hours apart. The standard suggested dosage for adults is 150 mg, given orally twice a day. However, this can be altered depending on the individual's medical condition and tolerance.

• The capsules should not be crushed, broken, or chewed and should be eaten whole with drinks.

• If a dosage is missed, it should be omitted, and the usual dosing schedule needs to be restarted; do not take extra doses.

• It is critical to keep Nintedanib in a tightly sealed container at room temperature, away from heat, moisture, and direct light, and out of the reach of children.

What Are the Side Effects of Nintedanib?

The most common side effects of Nintedanib include:

• Nausea.

• Diarrhea.

• Abdominal pain.

• Vomiting.

• Liver issues.

• Decreased appetite.

• Headache.

• Weight loss.

• High blood pressure.

• Dark urine.

• Pale stools.

• Severe stomach pain.

• Yellow eyes or skin.

• Weight gain.

• Depression.

• Slow heartbeat.

• Unusual tiredness or weakness.

• Muscle cramps and stiffness.

What Are the Things to Inform the Doctor Before Taking Nintedanib?

Before beginning Nintedanib or any drug, one should give their healthcare practitioner a detailed medical history and information about their current health. Here are some important things to tell their doctor before starting Nintedanib:

• Existing Medical Diseases: Inform doctors about any pre-existing medical diseases one possesses, especially if they are connected to liver difficulties, gastrointestinal troubles, blood disorders, or other serious health issues.

• Current Medications: List any medications one takes, including prescriptions, over-the-counter medications, vitamins, supplements, and herbal items. This information assists the doctor in determining potential Nintedanib interactions.

• Allergies: Please disclose any known allergies or adverse drug reactions, including allergies to Nintedanib or comparable pharmaceuticals.

• Pregnancy and Nursing: If the patient is pregnant, intend to become pregnant, or is nursing, they must inform the healthcare professional. The safety of Nintedanib during pregnancy and nursing should be further researched.

• Previous Treatments: Tell the doctor about prior treatments for IPF or other lung problems, such as drugs, therapies, or surgical procedures.

• Alcohol Usage: Talk to the doctor about alcohol usage since it may have an impact on liver function.

• Previous Unfavorable Reactions: Inform the physician if there is any unfavorable response to a medicine. This information aids in determining whether Nintedanib is right for the patient.

• Upcoming Operations: Inform a medical practitioner if one has any scheduled operations, including dental treatments. Before some operations, Nintedanib may need to be temporarily halted.

• Other Health Concerns: Talk about any other health issues or changes in symptoms one has experienced. Open communication with the doctor is critical for the best possible care.

Dietary Considerations

There are no known dietary restrictions related to Nintedanib. However, unless otherwise ordered by the healthcare practitioner, keeping a balanced and nutritious diet is typically recommended. Talk to the healthcare provider if one has any concerns regarding potential interactions between Nintedanib and particular foods or nutritional supplements.

Missed Dose

If one misses a dosage of Nintedanib, take it as soon as one recalls, unless their next scheduled dose is approaching. In that instance, skip the missing dosage and return to the normal dosing regimen. Remember to duplicate the dose to make up for a missing one.

Drug Storage

Follow the storage instructions supplied by the healthcare professional or on the box of the drug. In general, store Nintedanib at room temperature, away from light and moisture. Keep the medication in its original container and avoid storing it in the bathroom, which might have greater moisture levels. Keep the medicine out of children's reach.

For Doctors

Pharmacodynamics of Nintedanib:

The key aspects of the pharmacodynamics of Nintedanib include the following:

• Tyrosine Kinase Inhibition: Nintedanib inhibits a variety of receptor tyrosine kinases, including those associated with fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) receptors. Nintedanib disrupts cellular signaling pathways implicated in fibrosis by blocking these tyrosine kinases.

• Fibroblast Proliferation and Differentiation: Nintedanib inhibits the proliferation and differentiation of fibroblasts, which are cells that play an important part in the development of scar tissue (fibrosis). Growth factors such as FGF and PDGF activate fibroblasts, and Nintedanib's blocking of these pathways aids in modulating this process.

• Anti-Angiogenic Effects: Nintedanib has anti-angiogenic properties due to its inhibition of the VEGF receptor pathway. This implies it inhibits the creation of new blood vessels (angiogenesis), a component of the fibrotic process.

• Reduced Extracellular Matrix Synthesis: Fibrosis is characterized by increased synthesis and deposition of extracellular matrix components such as collagen. Nintedanib has been demonstrated to inhibit the synthesis and deposition of these matrix components, assisting in preventing or slowing scar tissue development.

Chemical Taxonomy of Nintedanib

• The molecular formula of Nintedanib is C31H33N504.

• Nintedanib belongs to the tyrosine kinase inhibitor family of drugs. It particularly inhibits tyrosine kinases associated with fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) receptors.

• Nintedanib exerts its antifibrotic effects by blocking these kinases, making it a targeted treatment for illnesses characterized by excessive fibrosis, such as idiopathic pulmonary fibrosis (IPF).

What Is Its Mechanism of Action?

Nintedanib's action mechanism is that it acts as a tyrosine kinase inhibitor, specifically targeting numerous receptor tyrosine kinases (RTKs) linked with fibrosis development. The following are the essential elements of Nintedanib's mechanism of action:

• Tyrosine Kinase Inhibition: Nintedanib inhibits tyrosine kinases associated with fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) receptors. Tyrosine kinases are important in cellular signaling pathways that control cell growth, proliferation, and differentiation.

• Fibroblast Activity Modulation: Fibroblasts produce collagen and other extracellular matrix components. FGF and PDGF promote fibroblast activity, which contributes to the development of fibrosis. Nintedanib's inhibition of these growth factor receptors controls fibroblast activity, lowering proliferation and differentiation.

• Anti-Angiogenic Effects: Nintedanib inhibits the vascular endothelial growth factor (VEGF) receptor pathway, resulting in anti-angiogenic actions. Generating new blood vessels is known as angiogenesis, and suppressing this process adds to the drug's antifibrotic effects.

• Reduced Extracellular Matrix Synthesis: Fibrosis is characterized by increased synthesis and deposition of extracellular matrix components such as collagen. Nintedanib has been demonstrated to inhibit the synthesis and deposition of these matrix components, assisting in preventing or slowing scar tissue development.

Toxicity of Nintedanib

Like many drugs, Nintedanib has the potential for adverse effects and toxicity. Nintedanib toxicity precipitates the following systemic issues:

• Gastrointestinal Adverse Effects: One of the most common adverse effects of Nintedanib is diarrhea, nausea, vomiting, and stomach discomfort. These symptoms can have an impact on some people's quality of life, and severe cases may result in dosage reductions or prescription withdrawal.

• Raised Liver Enzymes: Nintedanib has been linked to raised liver enzymes. During therapy, regular monitoring of liver function is usually advised. If severe liver enzyme increases occur, Nintedanib dose changes or withdrawal may be required.

• Bleeding Risk: Because Nintedanib is a tyrosine kinase inhibitor, it may increase the risk of bleeding. Individuals who have a history of bleeding problems or who use anticoagulant drugs should be constantly watched for indications of bleeding.

• Cardiovascular Events: Some research has linked Nintedanib to an increased risk of cardiovascular events, particularly in individuals with pre-existing cardiovascular problems. Before administering Nintedanib, healthcare practitioners may assess cardiovascular risk.

• Hepatic Impairment: Nintedanib is processed in the liver; thus, persons with hepatic impairment may be exposed to the medication at a higher rate. The use of Nintedanib in individuals with severe hepatic impairment should be examined cautiously.

• Interstitial Lung Disease (ILD): Although Nintedanib is used to treat idiopathic pulmonary fibrosis (IPF), drug-induced ILD is an uncommon adverse effect. Further assessment is required if new or worsening respiratory problems emerge.

Use in Specific Populations

Like many drugs, Nintedanib should be used with caution in select demographics, including certain patient groups. Considerations for using Nintedanib in certain groups include:

1. Pregnancy and Lactation:

• Pregnancy: Nintedanib may cause fetal damage and is not advised for usage during pregnancy. Women of reproductive age should take effective contraception during therapy and for at least three months following the final dosage.

• Lactation: It is unknown whether Nintedanib is excreted in human milk. Breastfeeding is not advised throughout Nintedanib therapy or at least three months following the final dosage.

2. Pediatric Use: The safety and efficacy aspects of Nintedanib in pediatric patients are yet to be determined. It is typically not advised to be used in the pediatric population.

3. Geriatric Use: In clinical trials, there were no overall differences in safety or efficacy between elderly and younger individuals. However, the senior population has a greater frequency of comorbidities. Therefore, caution should be used, and specific patient variables should be addressed.

4. Impaired Hepatic Function: Nintedanib is processed in the liver, and exposure in individuals with hepatic impairment may be increased. Individuals with moderate to severe hepatic impairment should be closely monitored.

5. Impairment of the Renal System: Nintedanib has little renal excretion. Hence, no dosage change is required in individuals with renal impairment. However, extreme caution is urged, and unique patient considerations should be considered.

6. ILD (Interstitial Lung Disease): Nintedanib is approved to treat idiopathic pulmonary fibrosis (IPF); however, it should be used with caution in individuals with other types of interstitial lung disease (ILD). The safety and effectiveness of Nintedanib in ILDs other than IPF are unknown.